GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Shiller PE Ratio

Redhill Biopharma (STU:2RH0) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Redhill Biopharma Shiller PE Ratio Historical Data

The historical data trend for Redhill Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Shiller PE Ratio Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Redhill Biopharma's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Shiller PE Ratio falls into.



Redhill Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Redhill Biopharma's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Redhill Biopharma's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.178/128.7287*128.7287
=0.178

Current CPI (Jun. 2023) = 128.7287.

Redhill Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -11.968 98.790 -15.595
201312 -14.600 98.326 -19.114
201403 11.568 99.695 14.937
201406 -14.720 100.560 -18.843
201409 -18.624 100.428 -23.872
201412 -19.464 99.070 -25.291
201503 -18.480 99.621 -23.880
201506 -24.948 100.684 -31.897
201509 -14.256 100.392 -18.280
201512 -18.950 99.792 -24.445
201603 -14.368 100.470 -18.409
201606 -21.360 101.688 -27.040
201609 -24.948 101.861 -31.528
201612 -26.544 101.863 -33.545
201703 -18.700 102.862 -23.402
201706 -21.360 103.349 -26.605
201709 -30.204 104.136 -37.337
201712 -16.900 104.011 -20.916
201803 -16.220 105.290 -19.831
201806 -17.120 106.317 -20.729
201809 -13.712 106.507 -16.573
201812 -10.548 105.998 -12.810
201903 -10.620 107.251 -12.747
201906 -14.160 108.070 -16.867
201909 -10.896 108.329 -12.948
201912 -10.800 108.420 -12.823
202003 -18.100 108.902 -21.395
202006 -14.208 108.767 -16.816
202009 -16.980 109.815 -19.905
202012 -23.016 109.897 -26.960
202103 -16.800 111.754 -19.352
202106 -19.920 114.631 -22.370
202109 -17.000 115.734 -18.909
202112 -17.700 117.630 -19.370
202203 -14.528 121.301 -15.418
202206 -7.568 125.017 -7.793
202209 -24.240 125.227 -24.918
202212 0.000 125.222 0.000
202303 18.680 127.348 18.883
202306 0.178 128.729 0.178

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Redhill Biopharma  (STU:2RH0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Redhill Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (STU:2RH0) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma (STU:2RH0) Headlines

No Headlines